Chercheur(e)

Dr Philippe De Wals

Obésité-Métabolisme

Y4283

philippe.dewals@criucpq.ulaval.ca

Domaine de recherche

Épidémiologie, santé des populations, prévention primaire, politiques publiques, économie de la santé, déterminants des comportements.

Description des travaux

Directeur scientifique de la Plateforme d'évaluation en prévention de l'obésité (PEPO) dédiée à l'évaluation des impacts des politiques, programmes et services et interventions visant à promouvoir de saines habitudes de vie et prévenir l'obésité et les maladies chroniques.

Prix et distinctions

2007 : Prix hommage de l’Association des médecins spécialistes en santé communautaire du Québec 2005 : Élu Membre étranger de l’Académie Royale de Médecine de Belgique 1998 : Récipiendaire de la Croix de Chevalier de l’Ordre de Léopold (Belgique), pour services rendus au pays 1991 : Récipiendaire de la Croix de Chevalier de l’Ordre de la Couronne (Belgique), pour services rendus au pays 1990 : Récipiendaire du Prix Jean Van Beneden (Belgique) pour l’excellence de la recherche en santé publique

Publications

Trier par année :

Dubé E, De Wals P, Ouakki M. Quality of life of children and their caregivers during an AOM episode: development and use of a telephone questionnaire.. Health Qual Life Outcomes 2010; 8(0):75.
De Wals P, Deceuninck G, Lefebvre B, Boulianne N, De Serres G. Effectiveness of Serogroup C Meningococcal Conjugate Vaccine: A 7-Year Follow-up in Quebec, Canada.. Pediatr Infect Dis J 2011; 30(7):566-9.
Dubé E, De Wals P, Gilca V, Boulianne N, Ouakki M, Lavoie F, Bradet R. Burden of acute otitis media on Canadian families.. Can Fam Physician 2011; 57(1):60-5.
De Wals P. Optimizing the acceptability, effectiveness and costs of immunization programs: the Quebec experience.. Expert Rev Vaccines 2011; 10(1):55-62.
Feikin DR1, Kagucia EW, Loo JD, Link-Gelles R, Puhan MA, Cherian T, Levine OS, Whitney CG, O'Brien KL, Moore MR; Serotype Replacement Study Group [including De Wals P].. Serotype-specific changes in invasive pneumococcal disease after pneumococcal conjugate vaccine introduction: a pooled analysis of multiple surveillance sites.. PLoS Med 2013; 10(9):e1001517.
Bernard S, Valiquette L, De Wals P, Nault V, Babakissa C, Cyr C, Boileau TC, Gagneur A. Burden of rotavirus disease: A population-based study in Eastern Townships, Quebec.. Can J Infect Dis Med Microbiol 2013; 24(3):138-42.
Kiely M, Sauvageau C, Dubé E, Deceuninck G, De Wals P. [Human papilloma virus: knowledge, beliefs and behavior of Quebec women].. Can J Public Health 2011; 102(4):303-7.
Zhou J, Lefebvre B, Deng S, Gilca R, Deceuninck G, Law DK, De Wals P, Tsang RS. Invasive Serogroup B Neisseria meningitidis in Quebec, Canada, 2003 to 2010: Persistence of the ST-269 Clone Since It First Emerged in 2003.. J Clin Microbiol 2012; 50(5):1545-51.
Gilca V, De Serres G, Boulianne N, Murphy D, De Wals P, Ouakki M, Trudeau G, Massé R, Dionne M. Antibody persistence and the effect of a booster dose given 5, 10 or 15 years after vaccinating preadolescents with a recombinant hepatitis B vaccine.. Vaccine 2013; 31(3):448-51.
Gilca R, Deceuninck G, Lefebvre B, Tsang R, Amini R, Gilca V, Douville-Fradet M, Markowski F, De Wals P. The changing epidemiology of meningococcal disease in Quebec, Canada, 1991-2011: potential implications of emergence of new strains.. PLoS One 2012; 7(11):e50659.
Madhi SA, De Wals P, Grijalva CG, Grimwood K, Grossman R, Ishiwada N, Lee PI, Nascimento-Carvalho C, Nohynek H, O'Brien KL, Vergison A, Wolter J. The Burden of Childhood Pneumonia in the Developed World: A Review of the Literature.. Pediatr Infect Dis J 2013; 32(3):e119-27.
De Wals P, Lefebvre B, Defay F, Deceuninck G, Boulianne N. Invasive pneumococcal diseases in birth cohorts vaccinated with PCV-7 and/or PHiD-CV in the province of Quebec, Canada.. Vaccine 2012; 30(45):6416-20.
De Wals P, Deceuninck G, Toth E, Boulianne N, Brunet D, Boucher RM, Landry M, De Serres G. Risk of Guillain-Barré syndrome following H1N1 influenza vaccination in Quebec.. JAMA 2012; 308(2):175-81.
Khuc NH, Tan B, Tuchscherer R, Rawson NS, De Wals P. Respiratory infection and otitis media visits in relation to pneumococcal conjugate vaccine use in Saskatchewan.. Can J Infect Dis Med Microbiol 2013; 24(4):179-84.
Owens S, De Wals P, Egeland G, Furgal C, Mao Y, Minuk G Y, Peters, P A, Simard M, Dewailly E. Public health in the Canadian Arctic: contributions from International Polar Year research.. Climatic Change 2012; 115(0):259-81.
Dodd CN, Romio SA, Black S, Vellozzi C, Andrews N, Sturkenboom M, Zuber P, Hua W, Bonhoeffer J, Buttery J, Crawford N, Deceuninck G, de Vries C, De Wals P, Garman P, Gimeno MV, Heijbel H, Hur K, Hviid A, Kelman J, Kilpi T, Chuang SK, Macartney K, Rett M, Lopez-Callada VR, Salmon D, Sanchez FG, Sanz N, Silverman B, Storsaeter J, Thirugnanam U, van der Maas N, Yih K, Zhang T, Izurieta H; the Global H1N1 GBS Consortium.. International collaboration to assess the risk of Guillain Barré Syndrome following Influenza A (H1N1) 2009 monovalent vaccines.. Vaccine 2013; 31(40):4448-58.
Gilca V, De Serres G, Boulianne N, Murphy D, Ouakki M, De Wals P, Trudeau G, Massé R, Dionne M.. Long-term persistence of immunity after vaccination of pre-adolescents with low doses of a recombinant hepatitis B vaccine.. Hum Vaccin Immunother 2013; 9(8):1685-90.
Kiely M, Sauvageau C, Dubé E, Deceuninck G, De Wals P.. Factors associated with HPV vaccination among adult women in Quebec.. Hum Vaccin Immunother 2013; 9(7):1421-4.
Brisson M, Melkonyan G, Drolet M, De Serres G, Thibeault R, De Wals P. Modeling the impact of one- and two-dose varicella vaccination on the epidemiology of varicella and zoster.. Vaccine 2010; 28(19):3385-97.
Deceuninck G, De Wals P, Boulianne N, De Serres G. Effectiveness of pneumococcal conjugate vaccine using a 2+1 infant schedule in Quebec, Canada.. Pediatr Infect Dis J 2010; 29(6):546-9.
Vickers DM, Anonychuk AM, De Wals P, Demarteau N, Bauch CT.. Evaluation of serogroup C and ACWY meningococcal vaccine programs: Projected impact on disease burden according to a stochastic two-strain dynamic model.. Vaccine 2013; 0(0):Epub.
Frère J, De Wals P, Ovetchkine P, Coïc L, Audibert F, Tapiero B.. Evaluation of several approaches to immunize parents of neonates against B. pertussis.. Vaccine 2013; 31(51):6087-91.
Massougbodji J, Le Bodo Y, Fratu R, De Wals P. Reviews examining sugar-sweetened beverages and body weight: correlates of their quality and conclusions.. Am J Clin Nutr 2014; 99(5):1096-104.
De Wals P, Lefebvre B, Markowski F, Deceuninck G, Defay F, Douville-Fradet M, Landry M. Impact of 2+1 pneumococcal conjugate vaccine program in the province of Quebec, Canada.. Vaccine 2014; 32(13):1501-6.
Le Meur JB, Lefebvre B, Proulx JF, Déry S, Pépin J, De Wals P. Impact of pneumococcal vaccines use on invasive pneumococcal disease in Nunavik (Quebec) from 1997 to 2010.. Int J Circumpolar Health 2014; 73(0):22691.
Vickers DM, Anonychuk AM, De Wals P, Demarteau N, Bauch CT. Evaluation of serogroup C and ACWY meningococcal vaccine programs: projected impact on disease burden according to a stochastic two-strain dynamic model.. Vaccine 2015; 33(1):268-75.
Montplaisir J, Petit D, Quinn MJ, Ouakki M, Deceuninck G, Desautels A, Mignot E, De Wals P. Risk of narcolepsy associated with inactivated adjuvanted (AS03) A/H1N1 (2009) pandemic influenza vaccine in Quebec.. PLoS One 2014; 9(9):e108489.
Cléophat JE, Le Meur JB, Proulx JF, De Wals P. Uptake of pneumococcal vaccines in the Nordic region of Nunavik, province of Quebec, Canada.. Can J Public Health 2014; 105(4):e268-72.
Deceuninck G, De Serres G, Boulianne N, Lefebvre B, De Wals P. Effectiveness of three pneumococcal conjugate vaccines to prevent invasive pneumococcal disease in Quebec, Canada.. Vaccine 2015; 33(23):2684-9.
De Wals P, Deceuninck G, De Serres G. Effectiveness of three pneumococcal conjugate vaccines to prevent invasive pneumococcal disease in Quebec, Canada.. Vaccine 2016; 34(18):2053-4.
Zhou Z, Gilca R, Deceuninck G, Boucher FD, Charest H, DE Wals P. Predictors of hospitalization for lower respiratory tract infection in children aged <2 years in the province of Quebec, Canada.. Epidemiol Infect 2016; 144(5):1035-44.
Law DK, Lefebvre B, Gilca R, Deng S, Zhou J, De Wals P, Tsang RS. Characterization of invasive Neisseria meningitidis strains from Québec, Canada, during a period of increased serogroup B disease, 2009-2013: phenotyping and genotyping with special emphasis on the non-carbohydrate protein vaccine targets.. BMC Microbiol 2015; 15(0):143.
Jones CH, Mohamed N, Rojas E, Andrew L, Hoyos J, Hawkins JC, McNeil LK, Jiang Q, Mayer LW, Wang X, Gilca R, De Wals P, Pedneault L, Eiden J, Jansen KU, Anderson AS. Comparison of Phenotypic and Genotypic Approaches to Capsule Typing of Neisseria meningitidis by Use of Invasive and Carriage Isolate Collections.. J Clin Microbiol 2016; 54(1):25-34.
Blouin C, Robitaille É, Le Bodo Y, Dumas N, De Wals P, Laguë J. Aménagement du territoire et politiques favorables à un mode de vie physiquement actif et à une saine alimentation au Québec.. Lien social et Politiques 2017; 78(0):19-48.
De Wals P, Zhou Z. Cost-Effectiveness Comparison of Monovalent C Versus Quadrivalent ACWY Meningococcal Conjugate Vaccination in Canada.. Pediatr Infect Dis J 2016; 0(0):.
Seib K, Pollard AJ, de Wals P, Andrews RM, Zhou F, Hatchett RJ, Pickering LK, Orenstein WA. Policy making for vaccine use as a driver of vaccine innovation and development in the developed world.. Vaccine 2017; 35(10):1380-1389.
Zhou Z, Deceuninck G, Lefebvre B, De Wals P. Forecasting Trends in Invasive Pneumococcal Disease among Elderly Adults in Quebec.. Can J Infect Dis Med Microbiol 2017; 2017(0):4347206.
De Wals P, Deceuninck G, Lefebvre B, Tsang R, Law D, De Serres G, Gilca V, Gilca R, Boulianne N. Impact of an immunization campaign to control an increased incidence of Serogroup B meningococcal disease in one region of Quebec, Canada.. Clin Infect Dis 2017; 64(9):1263-7.
Borrow R, Alarcón P, Carlos J, Caugant DA, Christensen H, Debbag R, De Wals P, Echániz-Aviles G, Findlow J, Head C, Holt D, Kamiya H, Saha SK, Sidorenko S, Taha MK, Trotter C, Vázquez Moreno JA, von Gottberg A, Sáfadi MA. The Global Meningococcal Initiative: global epidemiology, the impact of vaccines on meningococcal disease and the importance of herd protection.. Expert Rev Vaccines 2017; 16(4):313-328.
Anderson G, Deceuninck G, Zhou Z, Boucher FD, Bonnier Viger Y, Gilca R, DE Wals P. Hospitalisation for lower respiratory tract infection in children in the province of Quebec, Canada, before and during the pneumococcal conjugate vaccine era.. Epidemiol Infect 2017; 145(13):2770-6.
Le Bodo Y, Blouin C, Dumas N, De Wals P, Laguë J. The Quebec experience in promoting healthy lifestyles and preventing obesity: how can we do better?. Obes Rev 2017; 18(9):967-986.
De Wals P, Zhou Z. Cost-effectiveness Comparison of Monovalent C Versus Quadrivalent ACWY Meningococcal Conjugate Vaccination in Canada.. Pediatr Infect Dis J 2017; 36(7):e203-e207.
Massougbodji J, Lebel A, De Wals P. Individual and School Correlates of Adolescent Leisure Time Physical Activity in Quebec, Canada.. Int J Environ Res Public Health 2018; 15(3):E412.
De Wals P, Lefebvre B, Deceuninck G, Longtin J. Incidence of invasive pneumococcal disease before and during an era of use of three different pneumococcal conjugate vaccines in Quebec.. Vaccine 2018; 36(3):421-426.
Dubé È, Farrands A, Lemaitre T, Boulianne N, Sauvageau C, Boucher FD, Tapiero B, Quach C, Ouakki M, Gosselin V, Gagnon D, De Wals P, Petit G, Jacques MC, Gagneur A. Overview of knowledge, attitudes, beliefs, vaccine hesitancy and vaccine acceptance among mothers of infants in Quebec, Canada.. Hum Vaccin Immunother 2019; 15(1):113-120.
De Wals P. Commentary on paradoxical observations pertaining to the impact of the 13-valent pneumococcal conjugate vaccine on serotype 3 Streptococcus pneumoniae infections in children.. Vaccine 2018; 36(37):5495-5496.
Le Meur JB, Ayukawa H, Proulx JF, De Wals P. Prevalence of middle ear abnormalities from otitis media in relation with pneumococcal vaccine use in the Inuit population of Nunavik, province of Quebec, Canada.. Vaccine 2018; 36(34):5180-5186.
Gagneur A, Lemaître T, Gosselin V, Farrands A, Carrier N, Petit G, Valiquette L, De Wals P. A postpartum vaccination promotion intervention using motivational interviewing techniques improves short-term vaccine coverage: PromoVac study.. BMC Public Health 2018; 18(1):811.
Marten O, Koerber F, Bloom D, Bullinger M, Buysse C, Christensen H, De Wals P, Dohna-Schwake C, Henneke P, Kirchner M, Knuf M, Lawrenz B, Monteiro AL, Sevilla JP, Van de Velde N, Welte R, Wright C, Greiner W.. A DELPHI study on aspects of study design to overcome knowledge gaps on the burden of disease caused by serogroup B invasive meningococcal disease.. Health Qual Life Outcomes 2019; 17(1):87.
De Wals P, Lemeur JB, Ayukawa H, Proulx JF.. Middle ear abnormalities at age 5 years in relation with early onset otitis media and number of episodes, in the Inuit population of Nunavik, Quebec, Canada.. Int J Circumpolar Health 2019; 78(1):1599269.
Sings HL, De Wals P, Gessner BD, Isturiz R, Laferriere C, McLaughlin JM, Pelton S, Schmitt HJ, Suaya JA, Jodar L.. Effectiveness of 13-Valent Pneumococcal Conjugate Vaccine Against Invasive Disease Caused by Serotype 3 in Children: A Systematic Review and Meta-analysis of Observational Studies.. Clin Infect Dis 2019; 68(12):2135-2143.
De Wals P.. Commentary on paradoxical observations pertaining to the impact of the 13-valent pneumococcal conjugate vaccine on serotype 3 Streptococcus pneumoniae infections in children.. Vaccine 2018; 36(37):5495-5496.
LeMeur JB, Lefebvre B, Proulx JF, De Wals P.. Limited impact of pneumococcal vaccines on invasive pneumococcal disease in Nunavik (Quebec).. Can J Public Health 2019; 110(1):36-43.
Acevedo R, Bai X, Borrow R, Caugant DA, Carlos J, Ceyhan M, Christensen H, Climent Y, De Wals P, Dinleyici EC, Echaniz-Aviles G, Hakawi A, Kamiya H, Karachaliou A, Lucidarme J, Meiring S, Mironov K, Sáfadi MAP, Shao Z, Smith V, Steffen R, Stenmark B, Taha MK, Trotter C, Vázquez JA, Zhu B.. The Global Meningococcal Initiative meeting on prevention of meningococcal disease worldwide: Epidemiology, surveillance, hypervirulent strains, antibiotic resistance and high-risk populations.. Expert Rev Vaccines 2019; 18(1):15-30.
Gilca R, De Wals P, Nolan SM, Kitchin N, Eiden JJ, Jiang Q, Jones CH, Jansen KU, Anderson AS, Pedneault L.. A Longitudinal Epidemiology Study of Meningococcal Carriage in Students 13 to 25 Years Old in Quebec.. mSphere 2018; 3(6):e00427-18.
Gagneur A, Quach C, Boucher FD, Tapiero B, De Wals P, Farrands A, Lemaitre T, Boulianne N, Sauvageau C, Ouakki M, Gosselin V, Gagnon D, Petit G, Jacques MC, Dubé È. Promoting vaccination in the province of Québec: the PromoVaQ randomized controlled trial protocol.. BMC Public Health 2019; 19(1):160.
De Wals P, Espinoza-Moya ME, Béland D. Kingdon's Multiple Streams Framework and the Analysis of Decision-Making Processes Regarding Publicly-Funded Immunization Programs.. Expert Rev Vaccines 2019; 18(6):575-585.
Deceuninck G, Lefebvre B, Tsang R, Betala-Belinga JF, De Serres G, De Wals P. Impact of a mass vaccination campaign against Serogroup B meningococcal disease in the Saguenay-Lac-Saint-Jean region of Quebec four years after its launch.. Vaccine 2019; 37(31):4243-4245.
De Wals P. Epidemiology and Control of Meningococcal Disease in Canada: A Long, Complex, and Unfinished Story.. Can J Infect Dis Med Microbiol 2019; 2019(0):8901847.
Gagneur A, Battista MC, Boucher FD, Tapiero B, Quach C, De Wals P, Lemaitre T, Farrands A, Boulianne N, Sauvageau C, Ouakki M, Gosselin V, Petit G, Jacques MC, Dubé È. Promoting vaccination in maternity wards ? motivational interview technique reduces hesitancy and enhances intention to vaccinate, results from a multicentre non-controlled pre- and post-intervention RCT-nested study, Quebec, March 2014 to February 2015.. Euro Surveill 2019; 24(36):1800641.
Bélanger-Gravel A, Desroches S, Janezic I, Paquette MC, De Wals P. Pattern and correlates of public support for public health interventions to reduce the consumption of sugar-sweetened beverages.. Public Health Nutr 2019; 22(17):3270-3280.
Drolet M, Zhou Z, Sauvageau S, De Wals P, Gilca V, Amini R, Bénard É, Brisson M.. Effectiveness and Cost-Effectiveness of Vaccination Against Herpes Zoster in Canada: A Modelling Study. CMAJ 2019; 191(34):E932-E939.
Le Bodo Y, Elité F, Gagnon F, De Wals P.. Conditions influencing the adoption of a soda tax for public health: Analysis of the French case (2005-2012).. Food Policy 2019; 88(0):101765.
De Wals P, Menzies D, Divangahi M. Can BCG be useful to mitigate the COVID-19 pandemic? A Canadian perspective.. Can J Public Health 2020; 111(6):939-944.
De Wals P, Zhou Z, LeMeur JB, Proulx JF. Burden of respiratory infections and otitis media in the Inuit population of Nunavik, Quebec, Canada.. Int J Circumpolar Health 2020; 79(1):1799688.
Zhou Z, Gilca R, Deceuninck G, Boucher F, De Wals P. Hospitalizations for lower respiratory tract infections in children in relation to the sequential use of three pneumococcal vaccines in Quebec.. Can J Public Health 2020; 111(6):1041-1048.
Palmu AA, De Wals P, Toropainen M, Ladhani SN, Deceuninck G, Knol MJ, Sanders EAM, Miller E. Similar impact and replacement disease after pneumococcal conjugate vaccine introduction in hospitalised children with invasive pneumococcal disease in Europe and North America.. Vaccine 2021; 39(11):1551-1555.
Carazo S, Talbot D, Boulianne N, Brisson M, Gilca R, Deceuninck G, Brousseau N, Drolet M, Ouakki M, Sauvageau C, Barkati S, Fortin É, Carignan A, De Wals P, Skowronski DM, De Serres G. Single-dose mRNA vaccine effectiveness against SARS-CoV-2 in healthcare workers extending 16 weeks post-vaccination: a test-negative design from Quebec, Canada.. Clin Infect Dis 2022; 75(1):e805-e813.
Martinón-Torres F, Banzhoff A, Azzari C, De Wals P, Marlow R, Marshall H, Pizza M, Rappuoli R, Bekkat-Berkani R. Recent advances in meningococcal B disease prevention: real-world evidence from 4CMenB vaccination.. J Infect 2021; 83(1):17-26.
Deloria Knoll M, Bennett JC, Garcia Quesada M, Kagucia EW, Peterson ME, Feikin DR, Cohen AL, Hetrich MK, Yang Y, Sinkevitch JN, Ampofo K, Aukes L, Bacci S, Bigogo G, Brandileone MC, Bruce MG, Camilli R, Castilla J, Chan G, Chanto Chacón G, Ciruela P, Cook H, Corcoran M, Dagan R, Danis K, de Miguel S, De Wals P, Desmet S, Galloway Y, Georgakopoulou T, Hammitt LL, Hilty M, Ho PL, Jayasinghe S, Kellner JD, Kleynhans J, Knol MJ, Kozakova J, Kristinsson KG, Ladhani SN, Lara CS, León ME, Lepp T, Mackenzie GA, Mad'arová L, McGeer A, Mungun T, Mwenda JM, Nuorti JP, Nzoyikorera N, Oishi K, De Oliveira LH, Paragi M, Pilishvili T, Puentes R, Rafai E, Saha SK, Savrasova L, Savulescu C, Scott JA, Scott KJ, Serhan F, Setchanova LP, Sinkovec Zorko N, Skoczy?ska A, Swarthout TD, Valentiner-Branth P, van der Linden M, Vestrheim DF, von Gottberg A, Yildirim I, Hayford K, The Pserenade Team. Global Landscape Review of Serotype-Specific Invasive Pneumococcal Disease Surveillance among Countries Using PCV10/13: The Pneumococcal Serotype Replacement and Distribution Estimation (PSERENADE) Project.. Microorganisms 2021; 9(4):742.
Garcia Quesada M, Yang Y, Bennett JC, Hayford K, Zeger SL, Feikin DR, Peterson ME, Cohen AL, Almeida SCG, Ampofo K, Ang M, Bar-Zeev N, Bruce MG, Camilli R, Chanto Chacón G, Ciruela P, Cohen C, Corcoran M, Dagan R, De Wals P, Desmet S, Diawara I, Gierke R, Guevara M, Hammitt LL, Hilty M, Ho PL, Jayasinghe S, Kleynhans J, Kristinsson KG, Ladhani SN, McGeer A, Mwenda JM, Nuorti JP, Oishi K, Ricketson LJ, Sanz JC, Savrasova L, Setchanova LP, Smith A, Valentiner-Branth P, Valenzuela MT, van der Linden M, van Sorge NM, Varon E, Winje BA, Yildirim I, Zintgraff J, Knoll MD, The Pserenade Team. Serotype Distribution of Remaining Pneumococcal Meningitis in the Mature PCV10/13 Period: Findings from the PSERENADE Project.. Microorganisms 2021; 9(4):738.
Bennett JC, Hetrich MK, Garcia Quesada M, Sinkevitch JN, Deloria Knoll M, Feikin DR, Zeger SL, Kagucia EW, Cohen AL, Ampofo K, Brandileone MC, Bruden D, Camilli R, Castilla J, Chan G, Cook H, Cornick JE, Dagan R, Dalby T, Danis K, de Miguel S, De Wals P, Desmet S, Georgakopoulou T, Gilkison C, Grgic-Vitek M, Hammitt LL, Hilty M, Ho PL, Jayasinghe S, Kellner JD, Kleynhans J, Knol MJ, Kozakova J, Kristinsson KG, Ladhani SN, MacDonald L, Mackenzie GA, Mad'arová L, McGeer A, Mereckiene J, Morfeldt E, Mungun T, Muñoz-Almagro C, Nuorti JP, Paragi M, Pilishvili T, Puentes R, Saha SK, Sahu Khan A, Savrasova L, Scott JA, Skoczy?ska A, Suga S, van der Linden M, Verani JR, von Gottberg A, Winje BA, Yildirim I, Zerouali K, Hayford K, The Pserenade Team. Changes in Invasive Pneumococcal Disease Caused by Streptococcus pneumoniae Serotype 1 Following Introduction of PCV10 and PCV13: Findings from the PSERENADE Project.. Microorganisms 2021; 9(4):969.
Pépin J, De Wals P, Labbé AC, Carignan A, Parent ME, Yu J, Valiquette L, Rousseau MC. Influenza vaccine during the 2019-2020 season and COVID-19 risk: A case-control study in Québec.. Can Commun Dis Rep 2021; 47(10):430-434.
Pépin J, Labbé AC, Carignan A, Parent ME, Yu J, Grenier C, Beauchemin S, De Wals P, Valiquette L, Rousseau MC. Does BCG provide long-term protection against SARS-CoV-2 infection? A case-control study in Quebec, Canada.. Vaccine 2021; 39(50):7300-7307.
Martinón-Torres V, Banzhoff A, Azzari A, De Wals P, Marlow R., Marshall H, Pizza M, Rappuoli R, Bekkat-Berkan R.. Avances recientes en la prevención de la enfermedad meningocócica B: evidencia real de la vacunación con 4CMenB.. Vacunas 2021; 22(3):189-202.
Marshall HS, Andraweera PH, Ward J, Kaldor J, Andrews R, Macartney K, Richmond P, Krause V, Koehler A, Whiley D, Giles L, Webby R, D'Antoine H, Karnon J, Baird R, Lawrence A, Petousis-Harris H, De Wals P, Greenwood-Smith B, Binks M, Whop L. An Observational Study to Assess the Effectiveness of 4CMenB against Meningococcal Disease and Carriage and Gonorrhea in Adolescents in the Northern Territory, Australia-Study Protocol.. Vaccines (Basel) 2022; 10(2):309.
Asturias EJ, Bai X, Bettinger JA, Borrow R, Castillo DN, Caugant DA, Chacon GC, Dinleyici EC, Aviles GE, Garcia L, Glennie L, Harrison LH, Howie RL, Itsko M, Lucidarme J, Marin JEO, Marjuki H, McNamara LA, Mustapha MM, Robinson JL, Romeu B, Sadarangani M, Sáez-Llorens X, Sáfadi MAP, Stephens DS, Stuart JM, Taha MK, Tsang RSW, Vazquez J, De Wals P. Meningococcal disease in North America: Updates from the Global Meningococcal Initiative.. J Infect 2022; 85(6):611-622.
Carazo S, Skowronski DM, Brisson M, Sauvageau C, Brousseau N, Gilca R, Ouakki M, Barkati S, Fafard J, Talbot D, Gilca V, Deceuninck G, Garenc C, Carignan A, De Wals P, De Serres G. Estimated Protection of Prior SARS-CoV-2 Infection Against Reinfection With the Omicron Variant Among Messenger RNA-Vaccinated and Nonvaccinated Individuals in Quebec, Canada.. JAMA Netw Open 2022; 5(10):e2236670.
Fortin É, De Wals P, Talbot D, Ouakki M, Deceuninck G, Sauvageau C, Gilca R, Kiely M, De Serres G. Impact of the first vaccine dose on COVID-19 and its complications in long-term care facilities and private residences for seniors in Québec, Canada.. Can Commun Dis Rep 2022; 48(4):164-169.
Pépin J, Fox A, LeBlanc L, De Wals P, Rousseau MC. In the footsteps of Albert Calmette: an ecological study of TB, leprosy and potential exposure to wild-type Mycobacterium bovis.. Trans R Soc Trop Med Hyg 2022; 0(0):trac032.
Bélanger-Gravel A, Paquette MC, Espin-Espinoza A, Janezic I, Desroches S, De Wals P.. The influence of social norms in the context of reducing sugar-sweetened beverages consumption.. Public Health 2022; 213(0):28-33.
Skowronski DM, Febriani Y, Ouakki M, Setayeshgar S, El Adam S, Zou M, Talbot D, Prystajecky N, Tyson JR, Gilca R, Brousseau N, Deceuninck G, Galanis E, Fjell CD, Sbihi H, Fortin E, Barkati S, Sauvageau C, Naus M, Patrick DM, Henry B, Hoang LMN, De Wals P, Garenc C, Carignan A, Drolet M, Jassem AN, Sadarangani M, Brisson M, Krajden M, De Serres G. Two-Dose Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine Effectiveness With Mixed Schedules and Extended Dosing Intervals: Test-Negative Design Studies From British Columbia and Quebec, Canada.. Clin Infect Dis 2022; 75(11):1980-1992.
Carazo S, Skowronski DM, Brisson M, Barkati S, Sauvageau C, Brousseau N, Gilca R, Fafard J, Talbot D, Ouakki M, Gilca V, Carignan A, Deceuninck G, De Wals P, De Serres G. Protection against omicron (B.1.1.529) BA.2 reinfection conferred by primary omicron BA.1 or pre-omicron SARS-CoV-2 infection among health-care workers with and without mRNA vaccination: a test-negative case-control study.. Lancet Infect Dis 2023; 23(1):45-55.
Ouldali N, Deceuninck G, Lefebvre B, Gilca R, Quach C, Brousseau N, Tapiero B, De Wals P. Increase of invasive pneumococcal disease in children temporally associated with RSV outbreak in Quebec: a time-series analysis.. Lancet Reg Health Am 2023; 19(0):100448.
Deceuninck G, Brousseau N, Lefebvre B, Quach C, Tapiero B, Bui YG, Desjardins M, De Wals P. Effectiveness of thirteen-valent pneumococcal conjugate vaccine to prevent serotype 3 invasive pneumococcal disease in Quebec in children, Canada.. Vaccine 2023; 41(38):5486-5489.
Carazo S, Skowronski DM, Brisson M, Sauvageau C, Brousseau N, Fafard J, Gilca R, Talbot D, Ouakki M, Febriani Y, Deceuninck G, De Wals P, De Serres G. Effectiveness of previous infection-induced and vaccine-induced protection against hospitalisation due to omicron BA subvariants in older adults: a test-negative, case-control study in Quebec, Canada.. Lancet Healthy Longev 2023; 4(8):e409-e420.
Golden AR, Lefebvre B, Deceuninck G, Brousseau N, De Wals P, Quach C, Demczuk WHB, Martin I. Clonal diversity of Streptococcus pneumoniae serotype 19A collected from children Vaccine 2023; 41(44):6612-6618.

Dr Philippe De Wals

Domaine de recherche

Description des travaux

Prix et distinctions

Publications

Support tomorrow's medicine, now.